Next-Gen COVID-19 Vaccine Research
Join a paid Walter Reed Army Institute of Research study testing a unique vaccine to protect against current COVID-19 variant and future viruses.
Research conducted in Silver Spring, MD
Compensation up to $2,475
NO Prior COVID-19
Vaccine or Infection
In Good Health
18 - 55 Years Old
Fast Facts
About this research study:
The WRAIR vaccine has the potential to offer broad protection from SARS-CoV-2 and threat against new coronaviruses in human population.
The new vaccine is called spike ferritin nanoparticle (SpFN). Its multi-faced sphere design allows repetitive, ordered presentation of the coronavirus spike protein to the immune system, a strategy that may help provide broader protection. Scientists developed the vaccine considering the potential to approach protection not only from COVID-19 but also proactively against multiple coronavirus species and strains that may occur in the future.

The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the vaccine. The experimental vaccine in this study does not contain the virus and cannot cause you to become infected with the COVID-19 disease.
Additional Information
Why is this study being done?
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of dSpFN COVID-19 vaccine with Army Liposomal Formulation QS21 (ALFQ) adjuvant in healthy adults. A safe and effective vaccine is needed to prevent the COVID-19 disease, so we need to learn if the vaccine is safe and if it produces an appropriate immune response. The experimental vaccine cannot cause you to become infected with COVID-19. This experimental vaccine has been previously tested in animals, but this is the first time that it will be given to humans.
Is this study for me?
You may qualify for this study if you meet the following criteria.

Eligibility Criteria:
  • Be a healthy adult male or non-pregnant, non-breastfeeding female
  • Be between the ages of 18 & 55
  • Be willing and able to read, sign, and date the informed consent document as well as demonstrate an understanding of the study with a passing score (90% or greater) on the TOU by the third attempt, before study-related procedures are performed.
  • Be willing and able to participate in all planned study visits for the duration of the study.
  • Have the means to be contacted by telephone and/or video for remote follow-up visits as needed.
  • Must have a body mass index (BMI) ≥18.1 and <35.0 kg/m2.
  • Have NO previously documented COVID-19 infection.
  • Agree to refrain from donating blood or plasma outside of this study for the duration of your participation in this study.
  • Have acceptable screening laboratory results.
  • Biological females must have a negative pregnancy test at screening and continue to not become pregnant during the period of observation.
  • Biological females of reproductive capacity must use an acceptable method of birth control, beginning 30 days before enrollment, and until at least 60 days after last study injection (about 9 months in total)
  • Be in good health based on the investigator’s clinical judgment when considering findings from past medical history, medication use, vital signs, and physical examination.
You may not be allowed to participate in this study if any of the following apply to you:
  • Have plans to become pregnant or is currently pregnant or breastfeeding.
  • Have donated a unit of blood within 8 weeks before Day 1 (1st vaccine/placebo injection day) or plans to donate blood during the course of the study.
  • Have had a major surgery (per self-report) in the month prior to screening or plans to have major surgery during the study.
  • Have any past or current infection with HIV, Hepatitis C, or Hepatitis B.
  • Are unwilling to have their samples collected and stored for future research.
  • Emergency medical services personnel and/or Healthcare provider with patient contact in potentially high risk/high exposure settings as per screening physician’s assessment.
  • Have tattoos, scars, or other marks that would, in the opinion of the investigator, interfere with assessment of the injection site.
  • Have a known allergy or history of anaphylaxis, or other serious reaction to a vaccine, vaccine component, or latex.
  • Are currently participating in another clinical trial investigating a vaccine, drug, medical device, or clinical study that requires blood draws.
  • Received experimental treatment medicine within three months before first study injection day or plan to receive experimental treatment medicine during the course of the study.
  • Have a history of cancer.
  • Have diabetes mellitus (type I or II) and/or thyroid disease.
  • Have any current or past history of alcohol or drug abuse.
  • Current smoker or inhales vaporized nicotine “Vaping” daily. Current smoker is defined as an adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes.
  • Received blood products or immunoglobulin in the 3 months prior to screening or plans to receive during the course of the study.
  • Have an acute illness or temperature ≥38.0 oC on any study injection day or within 48 hours of planned study injection, however you can be reassessed by a study doctor if your illness resolves within 7 days.
  • Have a history of organ and/or stem cell transplantation.
  • Have any serious medical illness or condition involving the heart, liver, lungs, or kidneys.
  • Have a history of other chronic disease or condition including: asthma, autoimmune disease, sickle cell anemia, chronic hepatitis or cirrhosis, and chronic cardiac disease including high blood pressure (hypertension).
  • Have major psychiatric illness during the last 12 months.
  • Received an experimental COVID-19 vaccine outside of this study or a COVID-19 vaccine that has been given Emergency Use Authorization from the FDA. You will be asked if you have received any of these vaccines at each study visit.
  • Received live attenuated vaccine (e.g., oral polio, yellow fever, measles, etc.) from 30 days before Day 1 (1st study vaccine/placebo injection day) until 30 days after the last study injection.
  • Received killed or inactivated vaccine (e.g., injected polio, hepatitis A, rabies, pertussis, etc.) from 14 days before Day 1 (1st study vaccine/placebo injection day) until 30 days after the last study vaccination.
What will happen if I participate in the study?
If you qualify and choose to enroll in this study, you will receive injections at 2 or 3 separate visits. The study injections will be given by trained staff in the upper, outer part of the arm, similar to a vaccination you may receive at your doctor’s office.

You will return to the clinic on scheduled days following your study injection appointments. Follow-up visits will also be conducted by phone or video.

Study procedures at these visits will include medical history and physical exam, SARS-CoV-2 exposure risk assessment, blood draws, nasopharyngeal swab (nose swab) for COVID-19 testing, and urine pregnancy tests.
Will I be paid for being in this research study?
You will be paid for your time and efforts. The maximum compensation you can receive by participating in this study is $2475.00.

You can earn additional compensation for directing others who may be interested in this study to contact the CTC. You will receive $75 for each referred person who then attends a screening session and meets all inclusion and none of the exclusion criteria. This compensation is independent of the referred person’s decision to enroll.
Will it cost me anything to participate in this study?
There is no cost for the study medicine or study tests.